Company: LNAI
Filing Date: 2025-12-03
Form Type: 424B5
Source: 0001731122-25-001626
Chunk: 36

Company: Lunai Bioworks Inc.
Filing Date: 2025-12-03
Form: 424B5
Chunk 36
---
 Breast Cancer
(TNBC) is a subtype of breast cancer that is negative for estrogens receptor (ER) negative, progesterone receptor (PR) negative and human
epidermal growth factor receptor 2 (HER2). TNBC is characterized by its unique molecular profile, aggressive nature, and distinct metastatic
patterns that lack targeted therapies. TNBC is well known for its aggressive behavior and is characterized by onset at a younger age,
high mean tumor size, and higher-grade tumors.

Based upon our internal research,
literature reviews of ongoing clinical development for solid tumors, and recent advances in immune modulation, we believe we may have
the ability to design an innovative therapeutic vaccination platform that could potentially be used to treat some of the deadliest and
hard-to-treat solid tumors that include triple negative breast cancer.

Infectious Diseases:

RENB-HV12: Genetically Modified Allogeneic Dendritic Cell Therapeutic Vaccine as Potential Treatment Product for Long-term Remission of HIV; A Chronic Infectious Disease

The oncology therapeutic vaccine
technology could potentially be adapted to target infectious disease antigens and be a viable therapeutic approach in difficult to treat
chronic infectious diseases. As described above, the engineered allogenic dendritic cell drug substance is thought to be able to be loaded
with various cancer antigens for specific solid tumors but could or may be loaded with infectious disease antigens to elicit a more robust
immune response to viruses and other difficult to treat infections.

<div align='center'>2</div>

Renovaro Cube Overview

Renovaro Cube is an AI-driven
healthcare technology company focusing on the earliest possible detection of cancer and its recurrence. Renovaro Cube has developed a
proprietary AI platform that analyzes genetics using Explainable AI (as defined below) to provide earlier and more accurate cancer diagnosis.
This platform uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. This approach
is combined with differential molecular capabilities that are designed to identify, differentiate and pinpoint the exact source. Renovaro
Cube’s process also involves the mining of biomarker panels, which are integrated into a machine learning library referred to as
“RenovaroCube” to further enhance diagnosis.

Renovaro Cube also aims to utilize
its proprietary AI platform in the development of commercial products to support clinical, research and pharmaceutical organizations that
are trying to improve patient care through precision diagnosis, prediction of success of therapy, new drug discovery, treatment protocols